Update on the combination effect of macrolide antibiotics in community-acquired pneumonia

M. Emmet O'Brien, Marcos I. Restrepo, Ignacio Martin-Loeches

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Community-acquired pneumonia (CAP) is a leading cause of death from an infectious cause worldwide. Guideline-concordant antibiotic therapy initiated in a timely manner is associated with improved treatment responses and patient outcomes. In the post-antibiotic era, much of the morbidity and mortality of CAP is as a result of the interaction between bacterial virulence factors and host immune responses. In patients with severe CAP, or who are critically ill, there is a lot of emerging observational evidence demonstrating improved survival rates when treatment using combination therapy with a β-lactam and a macrolide is initiated, as compared to other antibiotic regimes without a macrolide. Macrolides in combination with a β-lactam antibiotic provide broader coverage for the atypical organisms implicated in CAP, and may contribute to antibacterial synergism. However, it has been postulated that the documented immunomodulatory effects of macrolides are the primary mechanism for improved patient outcomes through attenuation of bacterial virulence factors and host systemic inflammatory responses. Despite concerns regarding the limitations of observational evidence and the lack of confirmatory randomized controlled trials, the potential magnitude of mortality benefits estimated at 20-50% cannot be overlooked. In light of recent data from a number of trials showing that combination treatment with a macrolide and a suitable second agent is justified in all patients with severe CAP, such treatment should be obligatory for those admitted to an intensive care setting.

Original languageEnglish (US)
Pages (from-to)201-209
Number of pages9
JournalRespiratory Investigation
Volume53
Issue number5
DOIs
StatePublished - Sep 1 2015

Fingerprint

Macrolides
Pneumonia
Anti-Bacterial Agents
Lactams
Virulence Factors
Therapeutics
Mortality
Critical Care
Critical Illness
Cause of Death
Survival Rate
Randomized Controlled Trials
Guidelines
Morbidity

Keywords

  • Combination
  • Community-acquired-pneumonia
  • Macrolides
  • Sepsis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Update on the combination effect of macrolide antibiotics in community-acquired pneumonia. / Emmet O'Brien, M.; Restrepo, Marcos I.; Martin-Loeches, Ignacio.

In: Respiratory Investigation, Vol. 53, No. 5, 01.09.2015, p. 201-209.

Research output: Contribution to journalArticle

@article{0996bf62dbb8460e87019e3a7185584b,
title = "Update on the combination effect of macrolide antibiotics in community-acquired pneumonia",
abstract = "Community-acquired pneumonia (CAP) is a leading cause of death from an infectious cause worldwide. Guideline-concordant antibiotic therapy initiated in a timely manner is associated with improved treatment responses and patient outcomes. In the post-antibiotic era, much of the morbidity and mortality of CAP is as a result of the interaction between bacterial virulence factors and host immune responses. In patients with severe CAP, or who are critically ill, there is a lot of emerging observational evidence demonstrating improved survival rates when treatment using combination therapy with a β-lactam and a macrolide is initiated, as compared to other antibiotic regimes without a macrolide. Macrolides in combination with a β-lactam antibiotic provide broader coverage for the atypical organisms implicated in CAP, and may contribute to antibacterial synergism. However, it has been postulated that the documented immunomodulatory effects of macrolides are the primary mechanism for improved patient outcomes through attenuation of bacterial virulence factors and host systemic inflammatory responses. Despite concerns regarding the limitations of observational evidence and the lack of confirmatory randomized controlled trials, the potential magnitude of mortality benefits estimated at 20-50{\%} cannot be overlooked. In light of recent data from a number of trials showing that combination treatment with a macrolide and a suitable second agent is justified in all patients with severe CAP, such treatment should be obligatory for those admitted to an intensive care setting.",
keywords = "Combination, Community-acquired-pneumonia, Macrolides, Sepsis",
author = "{Emmet O'Brien}, M. and Restrepo, {Marcos I.} and Ignacio Martin-Loeches",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.resinv.2015.05.003",
language = "English (US)",
volume = "53",
pages = "201--209",
journal = "Respiratory Investigation",
issn = "2212-5345",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Update on the combination effect of macrolide antibiotics in community-acquired pneumonia

AU - Emmet O'Brien, M.

AU - Restrepo, Marcos I.

AU - Martin-Loeches, Ignacio

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Community-acquired pneumonia (CAP) is a leading cause of death from an infectious cause worldwide. Guideline-concordant antibiotic therapy initiated in a timely manner is associated with improved treatment responses and patient outcomes. In the post-antibiotic era, much of the morbidity and mortality of CAP is as a result of the interaction between bacterial virulence factors and host immune responses. In patients with severe CAP, or who are critically ill, there is a lot of emerging observational evidence demonstrating improved survival rates when treatment using combination therapy with a β-lactam and a macrolide is initiated, as compared to other antibiotic regimes without a macrolide. Macrolides in combination with a β-lactam antibiotic provide broader coverage for the atypical organisms implicated in CAP, and may contribute to antibacterial synergism. However, it has been postulated that the documented immunomodulatory effects of macrolides are the primary mechanism for improved patient outcomes through attenuation of bacterial virulence factors and host systemic inflammatory responses. Despite concerns regarding the limitations of observational evidence and the lack of confirmatory randomized controlled trials, the potential magnitude of mortality benefits estimated at 20-50% cannot be overlooked. In light of recent data from a number of trials showing that combination treatment with a macrolide and a suitable second agent is justified in all patients with severe CAP, such treatment should be obligatory for those admitted to an intensive care setting.

AB - Community-acquired pneumonia (CAP) is a leading cause of death from an infectious cause worldwide. Guideline-concordant antibiotic therapy initiated in a timely manner is associated with improved treatment responses and patient outcomes. In the post-antibiotic era, much of the morbidity and mortality of CAP is as a result of the interaction between bacterial virulence factors and host immune responses. In patients with severe CAP, or who are critically ill, there is a lot of emerging observational evidence demonstrating improved survival rates when treatment using combination therapy with a β-lactam and a macrolide is initiated, as compared to other antibiotic regimes without a macrolide. Macrolides in combination with a β-lactam antibiotic provide broader coverage for the atypical organisms implicated in CAP, and may contribute to antibacterial synergism. However, it has been postulated that the documented immunomodulatory effects of macrolides are the primary mechanism for improved patient outcomes through attenuation of bacterial virulence factors and host systemic inflammatory responses. Despite concerns regarding the limitations of observational evidence and the lack of confirmatory randomized controlled trials, the potential magnitude of mortality benefits estimated at 20-50% cannot be overlooked. In light of recent data from a number of trials showing that combination treatment with a macrolide and a suitable second agent is justified in all patients with severe CAP, such treatment should be obligatory for those admitted to an intensive care setting.

KW - Combination

KW - Community-acquired-pneumonia

KW - Macrolides

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=84940877479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940877479&partnerID=8YFLogxK

U2 - 10.1016/j.resinv.2015.05.003

DO - 10.1016/j.resinv.2015.05.003

M3 - Article

C2 - 26344609

AN - SCOPUS:84940877479

VL - 53

SP - 201

EP - 209

JO - Respiratory Investigation

JF - Respiratory Investigation

SN - 2212-5345

IS - 5

ER -